Cue Biopharma (CUE) News Today $1.09 +0.01 (+0.93%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Analysts Are Bullish on These Healthcare Stocks: Hookipa Pharma (HOOK), Cue Biopharma (CUE)November 18 at 7:38 AM | markets.businessinsider.comCue Biopharma Third Quarter 2024 Earnings: Beats ExpectationsNovember 17, 2024 | finance.yahoo.comCue Biopharma, Inc.: Cue Biopharma Announces Strategic Organizational TransitionNovember 16, 2024 | finanznachrichten.deCue Biopharma, Inc.: Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 16, 2024 | finanznachrichten.deCue Biopharma Reports Increased Revenue Amid Ongoing LossesNovember 16, 2024 | markets.businessinsider.comCue Biopharma’s Nasdaq Compliance Struggle: Risks and Implications for Future StabilityNovember 16, 2024 | markets.businessinsider.comCue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 14, 2024 | globenewswire.comCue names Daniel Baker interim CDO, CSO Amish Suri to transition to advisor roleNovember 14, 2024 | markets.businessinsider.comCue Biopharma Announces Strategic Organizational TransitionNovember 14, 2024 | markets.businessinsider.comCue Biopharma Announces Strategic Organizational TransitionNovember 14, 2024 | globenewswire.comCue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare ConferenceNovember 12, 2024 | finance.yahoo.comCue Biopharma: Strategic Shift and Promising Clinical Results Support Buy RecommendationNovember 12, 2024 | markets.businessinsider.comCue Biopharma presents ‘positive’ update from Phase 1 trials of CUE-101, CUE-102November 8, 2024 | markets.businessinsider.comCue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual MeetingNovember 8, 2024 | globenewswire.comShort Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Drops By 48.7%Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) saw a large drop in short interest in October. As of October 15th, there was short interest totalling 1,950,000 shares, a drop of 48.7% from the September 30th total of 3,800,000 shares. Based on an average daily trading volume, of 677,200 shares, the short-interest ratio is currently 2.9 days.October 26, 2024 | marketbeat.comCue Biopharma, Inc. (NASDAQ:CUE) Short Interest UpdateCue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) was the target of a large increase in short interest in September. As of September 30th, there was short interest totalling 3,800,000 shares, an increase of 6.7% from the September 15th total of 3,560,000 shares. Based on an average trading volume of 577,000 shares, the days-to-cover ratio is currently 6.6 days.October 16, 2024 | marketbeat.comCue Biopharma (NASDAQ:CUE) adds US$31m to market cap in the past 7 days, though investors from three years ago are still down 89%October 8, 2024 | finance.yahoo.comCue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual MeetingOctober 4, 2024 | globenewswire.comCue Biopharma (NASDAQ:CUE) Stock Quotes, Forecast and News SummarySeptember 27, 2024 | benzinga.comCue Biopharma (NASDAQ:CUE) Stock, Short Interest ReportSeptember 27, 2024 | benzinga.comCue Biopharma Announces Proposed Public OfferingSeptember 27, 2024 | finance.yahoo.comCue Biopharma Announces Pricing of $12.0 Million Public OfferingSeptember 26, 2024 | globenewswire.comCue Biopharma Announces Proposed Public OfferingSeptember 26, 2024 | globenewswire.comCue Biopharma Announces Proposed Public OfferingSeptember 26, 2024 | globenewswire.comCue Biopharma names Lucinda Warren as new chief business officerSeptember 11, 2024 | uk.investing.comCue Biopharma, Inc.: Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business OfficerSeptember 9, 2024 | finanznachrichten.deCue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business OfficerSeptember 9, 2024 | finance.yahoo.comCue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business OfficerSeptember 9, 2024 | globenewswire.comCue Biopharma to Present at The Promise of Interleukin-2 Therapy ConferenceSeptember 3, 2024 | finance.yahoo.comQ2 2024 Cue Biopharma Inc Earnings CallAugust 20, 2024 | ca.finance.yahoo.comCue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 20, 2024 | markets.businessinsider.comCue Biopharma, Inc. (NASDAQ:CUE) Q2 2024 Earnings Call TranscriptAugust 20, 2024 | msn.comCue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 19, 2024 | globenewswire.comCuts at Cue Biopharma include CEO salary, 25% of jobsJuly 26, 2024 | bizjournals.comCue Biopharma Receives ‘Buy’ Rating Amid Strategic Shift and Promising Autoimmune Therapeutics PipelineJuly 26, 2024 | markets.businessinsider.comCue Biopharma downsizes to focus on autoimmune pipelineJuly 26, 2024 | finance.yahoo.comApplied Intuition raises $300M four months after raising $250MJuly 25, 2024 | uk.finance.yahoo.comCue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital RequirementsJuly 25, 2024 | finance.yahoo.comCue Biopharma, Inc. (NASDAQ:CUE) Sees Significant Decrease in Short InterestCue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) was the target of a large decline in short interest in May. As of May 15th, there was short interest totalling 4,590,000 shares, a decline of 7.5% from the April 30th total of 4,960,000 shares. Based on an average daily volume of 295,700 shares, the short-interest ratio is currently 15.5 days.June 2, 2024 | marketbeat.comMedical Moonshots: 3 Biotech Stocks Set to SkyrocketMay 30, 2024 | investorplace.comCue Biopharma’s Promising Future: A Comprehensive Buy Rating JustificationMay 16, 2024 | markets.businessinsider.comCue Biopharma First Quarter 2024 Earnings: Beats ExpectationsMay 11, 2024 | finance.yahoo.comOppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)May 10, 2024 | markets.businessinsider.comCUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024May 10, 2024 | investorplace.comCue Biopharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | finance.yahoo.comCue Biopharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | finance.yahoo.comCue Biopharma to Present at the 20th Annual PEGS Boston SummitMay 8, 2024 | globenewswire.comCue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences ConferenceMay 7, 2024 | finance.yahoo.comCue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 24, 2024 | globenewswire.comForecasting The Future: 4 Analyst Projections For Cue BiopharmaApril 9, 2024 | markets.businessinsider.com Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] CUE Media Mentions By Week CUE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CUE News Sentiment▼0.270.46▲Average Medical News Sentiment CUE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CUE Articles This Week▼111▲CUE Articles Average Week Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Silence Therapeutics News Inhibrx News Zura Bio News Editas Medicine News Solid Biosciences News XBiotech News Corbus Pharmaceuticals News Amarin News Enanta Pharmaceuticals News ADC Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CUE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
